X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ADI-270 is an armored allogeneic “off-the-shelf” gamma delta CAR (chimeric antigen receptor) T cell therapy candidate which is being evaluated for the treatment of CD70 positive cancers.
Lead Product(s): ADI-270
Therapeutic Area: Oncology Product Name: ADI-270
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2024
Details:
The net proceeds will be used for the clinical development of ADI-001 for the treatment of autoimmune diseases and relapsed or refractory aggressive B-cell NHL with a current focus on mantle cell lymphoma patients.
Lead Product(s): ADI-001,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: ADI-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $98.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 25, 2024
Details:
The net proceeds will be used for the clinical development of ADI-001 for the treatment of autoimmune diseases and relapsed or refractory aggressive B-cell NHL focus on mantle cell lymphoma patients.
Lead Product(s): ADI-001
Therapeutic Area: Oncology Product Name: ADI-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $85.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 22, 2024
Details:
ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma.
Lead Product(s): ADI-001,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: ADI-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
ADI-001 is an allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors.
Lead Product(s): ADI-001,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: ADI-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2022
Details:
ADI-001, an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL, targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors.
Lead Product(s): ADI-001,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: ADI-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2022
Details:
ADI-925, a novel engineered chimeric adaptor (CAd) gamma delta T cell product candidate, is engineered to provide broad antitumor activity in multiple heme and solid malignancies.
Lead Product(s): ADI-925
Therapeutic Area: Oncology Product Name: ADI-925
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high grade aggressive Non-Hodgkin’s Lymphoma (NHL).
Lead Product(s): ADI-001,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: ADI-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR.
Lead Product(s): ADI-001,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: ADI-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
ADI-001 exhibited robust in vitro and in vivo tumor growth inhibition in multiple human lymphoma cell lines, with adaptive and innate mechanisms contributing to its anti-tumor activity.
Lead Product(s): ADI-001,Fludarabine Phosphate,Bendamustine Hydrochloride
Therapeutic Area: Oncology Product Name: ADI-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
